Author:
Naguib Gina Gamal,Farid Amir,Hassan Mohamed,Elshafie Ahmed,Shazly Yehia El,Shaker Mohamed Kamal,Ezzat Haitham,Safwat Eslam,Ahmed Ossama Ashraf,Dabbous Hany,Sherief Ahmed Fouad,Hassany Mohamed,Elserafy Magdy,Elsayed Manal Hamdy
Reference31 articles.
1. World Health Organization (WHO), Hepatitis C Fact Sheet No164; (updated Jul 2017).
2. Ministry of Health and population [Egypt], El-Zanaty and associates [Egypt], ICF International. Egypt Health Issues Survey 2015. Cairo, Rockville, MD: Ministry of Health and Population, ICF International; 2015.
3. Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals;Lee;Cancers,2020
4. Hong CM, Liu CH, Su TH, et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data. J Microbiol Immunol Infect, 2020, 53:569-77, pii: S1684-1182(18)30403-1.
5. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients;Khan;PLoS ONE,2020
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献